Interaction of Resveratrol and Genistein with Nucleic Acids

Usha, S.; Johnson, Irudayam Maria; Malathi, R.

doi:10.5483/bmbrep.2005.38.2.198

Cited by 46 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). Resveratrol has been shown to interact with protein kinase C, 10 aromatase, 11 hetero-dimeric alphaVbeta3 integrin, 12 multidrug resistance protein 1, 13 β-lactoglubulin, 14 human serum albumin, 15 human DNA topoisomerase II, 16 plasma lipoprotein, 17 nucleic acids, 18 DNA polymerase α and δ, 19 myeloperoxidase, 20 tubulin, 21 estrogen receptor α and β, 22 F1-ATPase, 23 sulfonyl urea receptors, 24 cytosolic alcohol dehydrogenase, 25 amyloid fibrils 26 and dihydronicotinamide riboside quinone reductase 2 (NQO2). 27 In most cases interaction of resveratrol with these proteins leads to inactivation of the molecule.…”

Section: Molecular Targets Of Resveratrolmentioning

confidence: 99%

Resveratrol: A multitargeted agent for age-associated chronic diseases

Harikumar¹,

Aggarwal²

2008

Cell Cycle

472

334

View full text Add to dashboard Cite

Extensive research within the last decade has revealed that most chronic illnesses such as cancer, cardiovascular and pulmonary diseases, neurological diseases, diabetes, and autoimmune diseases exhibit dysregulation of multiple cell signaling pathways that have been linked to inflammation. Thus mono-targeted therapies developed for the last two decades for these diseases have proven to be unsafe, ineffective and expensive. Although fruits and vegetables are regarded to have therapeutic potential against chronic illnesses, neither their active component nor the mechanism of action is well understood. Resveratrol (trans-3, 5, 4'-trihydroxystilbene), a component of grapes, berries, peanuts and other traditional medicines, is one such polyphenol that has been shown to mediate its effects through modulation of many different pathways. This stilbene has been shown to bind to numerous cell-signaling molecules such as multi drug resistance protein, topoisomerase II, aromatase, DNA polymerase, estrogen receptors, tubulin and F1-ATPase. Resveratrol has also been shown to activate various transcription factor (e.g., NFκB, STAT3, HIF-1α, β-catenin and PPAR-γ), suppress the expression of antiapoptotic gene products (e.g., Bcl-2, Bcl-X L , XIAP and survivin), inhibit protein kinases (e.g., src, PI3K, JNK and AKT), induce antioxidant enzymes (e.g., catalase, superoxide dismutase and hemoxygenase-1), suppress the expression of inflammatory biomarkers (e.g., TNF, COX-2, iNOS and CRP), inhibit the expression of angiogenic and metastatic gene products (e.g., MMPs, VEGF, cathepsin D and ICAM-1), and modulate cell cycle regulatory genes (e.g., p53, Rb, PTEN, cyclins and CDKs). Numerous animal studies have demonstrated that this polyphenol holds promise against numerous age-associated diseases including cancer, diabetes, Alzheimer, cardiovascular and pulmonary diseases. In view of these studies, resveratrol's prospects for use in the clinics are rapidly accelerating. Efforts are also underway to improve its activity in vivo through structural modification and reformulation. Our review describes various targets of resveratrol and their therapeutic potential.

show abstract

Section: Molecular Targets Of Resveratrolmentioning

confidence: 99%

Resveratrol: A multitargeted agent for age-associated chronic diseases

Harikumar¹,

Aggarwal²

2008

Cell Cycle

472

334

View full text Add to dashboard Cite

show abstract

“…The formation of a double bond between carbon 2 and 3 of naringenin results in the production of apigenin (5,7,4'-trihydroxyflavone). Compared with the flavanones, flavones including isoflavones exhibit diverse biological properties including antioxidative, antitumor, antiinflammatory, antibacterial, antiviral, and antiatherosclerotic activities (3)(4)(5). Thus, conversion of flavanone into flavone is of great interests due to the various biological activities of flavone.…”

Section: Introductionmentioning

confidence: 99%

Characterization of flavone synthase I from rice

Lee¹,

Kim²,

Kim³

et al. 2008

BMB Reports

View full text Add to dashboard Cite

“…We hypothesized that the absorbance of thalidomide may be diminished more dramatically by the secondary structure of a DNA fragment that was bound more tightly by this dug (29). As shown in Fig.…”

Section: Thalidomide Down-regulates Bfgf Transcription and Translatiomentioning

confidence: 99%

The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma

Mei¹,

Wu²

2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Thalidomide is considered to be a potent antiangiogenic and immunomodulatory drug for cancer therapy. Earlier clinical studies have found that patients responding to this drug often had high plasma levels of basic fibroblast growth factor (bFGF). This cytokine is a proangiogenic factor overexpressed in many tumors and is also a regulator of limb development; hence, it might be a target of thalidomide. Using U-87 MG cell lines, we found that thalidomide, especially when encapsulated in a liposome, down-regulated the transcription and translation of the FGF-2 gene by interacting with G-rich regions present in the promoter and the internal ribosome entry site of its transcript at concentrations much lower than therapeutic serum concentrations. Thalidomide treatment also dramatically suppressed the anchorage-independent growth of U-87 MG and other glioma cells by over a thousand fold without affecting its anchorage-dependent growth, which may be accomplished by knocking down endogenous bFGF expression in these cells. Accordingly, the addition of recombinant bFGF partially restored the anchorageindependent growth of these cells. Our data suggest that by targeting the G-rich regions of bFGF, thalidomide (at 0.1 Mg/mL) can reduce cellular bFGF levels and affect tumor anchorage-independent growth, the hallmark of tumorigenicity. Our results are promising for future clinical investigations using low doses of thalidomide.

show abstract

Interaction of Resveratrol and Genistein with Nucleic Acids

Cited by 46 publications

References 12 publications

Resveratrol: A multitargeted agent for age-associated chronic diseases

Resveratrol: A multitargeted agent for age-associated chronic diseases

Characterization of flavone synthase I from rice

The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma

Contact Info

Product

Resources

About